Drug intelligence / Profile preview

alefacept + betamethasone dipropionate

Development stage: Discontinued
Lead developer: Biogen
Modality: Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intramuscular, Intravenous, Topical

Overview

Alefacept + betamethasone dipropionate is a combination therapy used for the treatment of moderate to severe plaque psoriasis. Alefacept is a recombinant fusion protein that binds CD2 and interferes with lymphocyte activation, while betamethasone dipropionate is a topical corticosteroid that helps relieve redness, itching, swelling, and other discomforts caused by psoriasis. The combination aims to provide enhanced therapeutic effect through dual mechanisms of action.

Targets

GR (Glucocorticoid receptor)CD2 (T-cell Surface Antigen CD2)

Beyond the preview

Go deeper on alefacept + betamethasone dipropionate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alefacept + betamethasone dipropionate.

Explore the full profile